KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Debt (2016 - 2025)

Astrazeneca has reported Non-Current Debt over the past 11 years, most recently at $24.7 billion for Q4 2025.

  • Quarterly results put Non-Current Debt at $24.7 billion for Q4 2025, down 6.76% from a year ago — trailing twelve months through Dec 2025 was $24.7 billion (down 6.76% YoY), and the annual figure for FY2025 was $24.7 billion, down 6.76%.
  • Non-Current Debt for Q4 2025 was $24.7 billion at Astrazeneca, down from $26.5 billion in the prior quarter.
  • Over the last five years, Non-Current Debt for AZN hit a ceiling of $28.1 billion in Q4 2021 and a floor of $22.4 billion in Q4 2023.
  • Median Non-Current Debt over the past 5 years was $24.7 billion (2025), compared with a mean of $24.9 billion.
  • Biggest five-year swings in Non-Current Debt: soared 60.72% in 2021 and later decreased 18.37% in 2022.
  • Astrazeneca's Non-Current Debt stood at $28.1 billion in 2021, then decreased by 18.37% to $23.0 billion in 2022, then dropped by 2.61% to $22.4 billion in 2023, then increased by 18.52% to $26.5 billion in 2024, then fell by 6.76% to $24.7 billion in 2025.
  • The last three reported values for Non-Current Debt were $24.7 billion (Q4 2025), $26.5 billion (Q4 2024), and $22.4 billion (Q4 2023) per Business Quant data.